The aim of this study is to investigate the expression of the chromosomal passenger protein Aurora B and its activated (phosphorylated) form in a large series of human oral squamous cell cancers (OSCC) and to evaluate its clinical and prognostic significance. Western blotting analysis revealed overexpression of both Aurora Band Thr-232 Phopsho-Aurora B in OSCC lines as compared to normal keratinocytes and bladder cancer cells. Furthermore, protein expression was analysed by immunohistochemistry in 101 OSCC of different site, stage and histological grade and in normal peritumoural areas. The intracellular localization of Aurora B in tumour cells was mainly nuclear, especially in proliferative areas, and significant overexpression was found in tumours in comparison to normal peritumoural areas (P=O.012). Staining results were correlated with clinicopathological parameters and long-term followup, and a significant association was found between protein expression and tumour stage (stage II, III and IV vs stage I, P=0.030) and size «2cm vs >2cm, P=0.010). Cox regression analysis confirmed a poorer disease-free survival in cases with high expression of Aurora B protein. Kaplan-Meier curves showed shorter time to progression in patients with high levels of Aurora B expression (p<0.05). Moreover, the tumoral group with nuclear Aurora B immunolocalization had the worst prognosis (P=0.0364 in disease free survival). Our results suggest that assessing Aurora B expression might help in patients' risk stratification and serve as a novel therapeutic target in advanced OSCCs.
techniques and radiation therapy (I). While the epidemiology of these common neoplasms is well described, much work remains to elucidate the molecular mechanisms involved in their pathogenesis, in order to develop new treatment modalities and improve their outcome.
Aurora B serine-threonine kinase is a member of the chromosomal passenger family of proteins, along with inner centromere protein (lNCENP) and survivin; they are all required for proper coordination of chromosomal and cytoskeletal events in mitosis, such as chromosome condensation and segregation, microtubule-kinetochore interaction, spindle checkpoint control and cytokinesis (2) . In particular, the expression of Aurora B peaks during the G2/M phase transition and in the M phase of the cell cycle, and induces decondensation of chromatin by phosphorylation ofH3 histone (3) .
A large body of data has demonstrated the presence of survivin deregulation in tumour development, while the role of the other members of this group has not been so intensely investigated (4); indeed, it is broadly assumed that both survivin and Aurora B share the same pattern oflocalization (5) .
As a possible cause of aneuploidy and subsequent chromosome instability (6) , loss of the mitotic regulation is currently believed to be involved in human carcinogenesis, and is mainly found in association with aggressive malignancies, including glioblastoma and thyroid anaplastic carcinoma (6) (7) (8) ; to date, a great deal of evidence has suggested that aurora B overexpression is related to invasiveness and clinical outcome in many solid tumours (9) (10) (11) .
Recently, in a series of 40 OSCC, evaluation of Aurora B expression by immunohistochemistry showed a positive association with some clinicopathological parameters (cell proliferation, induction of multinuclear cells, histological differentiation, and metastasis) (12) .
The kinase activity of Aurora B has been previously shown by detecting histone H3 phosphorylation. Aurora B has been reported to phosphorylate histone H3, centromere protein A (CENP-A) and inner centromere protein (lNCENP), vimentin and other molecules. Aurora B directly binds INCENP, and INCENP is required to correctly target Aurora B to centromeres and the central spindle. The phosphorylation of histone H3 at Ser-10 Ser-28, when Aurora B is co-expressed with INCENP, indicates that Aurora B is activated through its interaction with INCENP. Yoshihiro Yasui et al. (13) reported that human aurora B is phosphorylated at Thr-232 through interaction with the INCENP. This phosphorylation may occur by means of an autophosphorylation mechanism and is essential for the Aurora B kinase activity (13) . Particularly, Aurora B kinase can be considered an important therapeutic target. New promising kinase inhibitors are in development and they may have been added to the cancer therapeutic armamentarium after ongoing clinical trials (14) . These drugs are capable of both inhibiting histone H3 phosphorylation, the specific substrate of Aurora B kinase and also modulating the cytotoxicity of contemporary chemotherapy regimens. The role of specific Aurora B kinase inhibitors is appropriately reviewed by Yeung SC et al. (15) .
In this study we analysed the expression of Aurora B and its activated (phosphorylated) form in 101 OSCCs, with the aim to better define the causative and prognostic-therapeutic role of such chromosomal passenger protein in a large series of such tumours.
MATERIALS AND METHODS

Patients
The study was approved by the Ethics Committee of the Universita Politecnica delle Marche, Ancona, and all patients gave written informed consent. From the databank of the Oral Surgery Registry of the institution, 101 patients with OSCC undergoing oral and maxillofacial surgery with curative intention between 1990 and 2000 were randomly chosen, and samples were retrieved from the Department of Pathology. Each tumour was fixed in formalin and embedded in paraffin. Clinical charts were reviewed and follow-up data were collected. All slides were reviewed by 2 pathologists at the Department of Surgical Science, Section of Anatomic Pathology and Cytopathology, University of Foggia. Tumour stage and grade were assigned according to the WHO classification of malignant tumours of the head and neck (16) . Moreover, invasion status of each tumour was evaluated according to the criteria of Yamamoto et aI., 1983 (17) , as follows: Grade I, a well-defined borderline; Grade 2, a less marked borderline; Grade 3, no distinct borderline; and Grade 4, diffuse invasion (Grade 4C, cord-like type; Grade 4D, widespread type).
Cel/lines
The NHEK normal human epithelial keratinocyte line and the bladder cell line (SG65) were obtained from Interlab Cell Line Collection, Genova, Italy; the PE 15 and PE I5D cell lines originated from a human dedifferentiated OSCC of the tongue; the PE 34 cell line originated from a human basaloid well differentiated OSCC; the PE 41 and PE 46 OSCC cell lines originated from a human moderately differentiated OSCC; the PE 49 cell lines were obtained from a human poorly differentiated OSCC of the tongue. The HSC2 cell line was obtained from human squamous carcinoma cells of the mouth. The SG65 cell line was obtained from human bladder tumor. All oral cell lines were kindly supplied by Prof. A. Mariggio, University of Bari. All cell lines were cultured at 37°C in Dulbecco's Modified Eagles Medium (DMEM), supplemented with 10% foetal bovine serum (FBS), 0.075% sodium bicarbonate, 0.6 mg/ml L-glutamine.
Western blotting
Expression levels of both Aurora Band phospho-Aurora B proteins were determined by immunoblotting. Cells were lysed in RIPA lysis buffer containing protease and phosphatase inhibitors. Equal amounts of lysate were separated on 12.5% SDS-PAGE using a Mini V-8.10 Vertical Gel Electrophoresis System (Gibco BRL, Gaithersburg, MD, USA). The Precision Plus Protein standard All Blue (Bio-Rad Laboratories, USA) was used to determine protein size. After electrophoresis, proteins were transferred onto nitrocellulose membranes (Whatman, Schleicher & Schuell, Germany) and non-specific binding blocked by 5% w/v non-fat dry milk in TBST buffer (50mM Tris-HCI 0.2M NaCl, pH 7.6, 0.1% Tween-20) at room temperature for I hour, and then washed three times for 5 min each with TBST. The membranes were incubated sequentially with antibodies against Aurora B at 1:2000 (NB I00-294, Novus Biologicals) and Phospho-Aurora A(Thr288)/Aurora B(Thr232)/Aurora C(Thr398) at I: 1000 (Cell Signalling Technology, USA, # 2914) in TBST buffer with 5% BSA at 4°C overnight. After washing with TBST, the membranes were incubated with secondary antibody conjugated to peroxidase (I: 10000, Pierce Biotechnology, USA) in TBST buffer with 5% BSA for I h. For detection, the ECL (Amersham Biosciences, USA) system was used according to the manufacturer's instructions. B-actin (1:5000, Santa Cruz Biotechnology, USA) was used as a protein loading control.
Immunohistochemistry
Expression of Aurora B was evaluated by immunohistochemistry (IHC) on 4-j.lm-thick tissue section obtained from paraffin-embedded specimens fixed in 10% neutral buffered formalin, using linked streptavidin-biotin horseradish peroxidase technique (LSAB-HRP) as described previously (18) . The sections were deparaffinised and hydrated by passing through xylene and a graded series of ethanol, followed by washing in distilled water. Antigen retrieval was carried out in a microwave (the 1st time at 650 W for 3 min, then 2 times at 350 W, in a 10 mM citrate buffer; pH 6.0). The sections were incubated with primary polyclonal Aurora B antibody (NBIOO-294, Novus Biologicals, dilution I: 3000) at 24°C. Immunostaining was performed by the avidin-biotin peroxidase complex technique (DAKO, Denmark) for 30 min according to the manufacturer's instructions and using 3,3'-diaminobenzidine tetrahydrochloride (DAB, Dako Cytomation) as a chromogen; subsequently, the slides were counterstained with Meyer's haematoxylin. Negative controls were obtained by omitting the primary antibody. Positive control was performed on paraffin-embedded human prostate cancer in all runs. The slides were evaluated by two independent pathologists without knowledge of the clinical data. Inter-rate reliability between the two investigators examining the immunostained sections was assessed by the Cohen's K test, yielding K values higher than 0.70 in almost all instances. For the quantitative statistical analysis, the percentage ofstained cells (number of positive cells over total tumour cells) and intensity of staining for each case were calculated evaluating 10 highpower representative fields (X400) on complete tumour sections using light microscopy (OLYMPUS BX4I).
Statistical analysis
Statistical analyses were performed using Stanton Glantz statistical software 3 (MS-DOS), SPSS statistical software and GraphPad Prism software version 4.00 for Windows (Graph Pad software San Diego California, USA; www.graphpad.com). P-values <0.05 were considered significant. The one-way analysis of variance (ANOVA) and the Student-Newman-Keuls tests were used to study the differences between the groups, then Cox regression multivariate analysis was performed. Significant differences concerning tumour survival rate were calculated using the Kaplan-Meier method and Chisquare Test. For the evaluation of tumour survival rate, the patients were surveyed at the time oftheir last tumour-free clinical follow-up appointment or at the patient's death.
RESULTS
Clinical and pathological data
Only cases with a complete and long-term clinical, post-surgical follow-up were included in the analysis. The patients' clinical and pathological 
Immunohistochemistry
The intracellular localization of Aurora B in tumour cells was mainly nuclear, especially in proliferative areas, as evaluated by mitotic rate and ki-67 immunostaining in serial sections (data not shown). In addition, a mixed nuclear and 11 . ,
Fig. 2. Expression of Aurora B in oral carcinogenesis. Staining is present in focal parabasal nuclei in epithelial hyperplasia (a) and in basal mitoses in a dysplastic lesion (b). In a well differentiated osee Aurora B is expressed in tumoral front of invasion (c), and in moderately differentiated tumours is localized throughout invasive strands ofcells both in cytoplasms and in nuclei, preferentially in areas showing high mitotic index (d, dl, d2, e) and atypical mitoses (f).
In a case featuring pleomorphic nuclei and large nucleoli. Aurora B expression was exclusively cytoplasmic (g) (LSAB-HRP, hematoxylin-counterstained; original magnification have been reportedfor each picture in the lower right corner; asterisks for nuclear immunostaining; arrowheads for mitoses). cytoplasmic expression was detected in most tumour areas (Fig. 2) .
Immunohistochemical nuclear and/or cytoplasmic staining of Aurora B (percentage of positive cancer cells ranging from 5 to 100%) was observed in all cases of osee, with an overall higher degree of protein immunostaining than normal peritumoural oral epithelium (P<0.05).
In all, 10 cases revealed a low level positivity, 20 cases a moderate level positivity and 71 cases a high level positivity. First, immunohistochemical findings were applied to perform univariate analysis (ANOVA, Student-Neuman-Keuls), which evidenced a statistical significant association with tumour size and stage (P<0.05). Data regarding expression of Aurora B in relation to clinical and pathological characteristics of our study population (sex, age, tumour site and stage, histological grade) are shown in Table I . Subsequently, Cox multivariate regression analysis (MVA) was used to confirm independent predictors of outcome among histopathological and immunohistochemical variables that showed statistically significant correlation by univariate analyses. A statistical significant association was found between high Aurora B expression and shorter disease-free survival (P=0.027). No statistical association was observed with other investigated covariables (tumour grade and stage) (see Table II ).
When considering patients' survival, we stratified osee patients in two different prognostic groups, according to immunohistochemical findings: group I (moderate to high Aurora B expression, > 60% of neoplastic cells) and group 2 (low expression, <60% of neoplastic cells). By the statistic Kaplan-Meier curves, we first analysed clinical data, referring to overall (OS) and disease-free survival (DFS) of osee patients according to Aurora B expression ( Fig. 3 : p < 0.05 for DFS; no significant p for OS: data not shown).
Then, we stratified osee patients according to intracellular distribution of Aurora B. Kaplan-Meier curve showed that tumours with nuclear Aurora B immunolocalization had the worst prognosis ( Fig. 4 : p < 0.05 for DFS; no significant p for OS: data not shown).
DISCUSSION
Several in vitro and in vivo studies have addressed the association ofAurora kinases with carcinogenesis (19) (20) ; aberrant expression of such proteins have been demonstrated in specific human tumours, both in early disease and in advanced stages, with poor prognosis. As for the oncogenic potential of Aurora B kinase, it seems to act indirectly by potentiating other oncogenes (such as H-Ras) or by inducing genomic instability, rather than in a direct manner (21) (22) . Aurora B in normal cells accumulates at the G2/ M phase of the cell cycle (23) , and is localized first to inner-centromeric chromatin in prometaphase, then to the spindle midzone (thus the name 'equatorial-kinase') during telophase, and finally in the midbody throughout cytokinesis (19) , so to promote accurate chromosome attachment and segregation, kinetochore biorientation by regulating kinetochore-microtubule interactions, activation of the spindle assembly checkpoint and cytokinesis (24) ; its RNA interference-mediated inhibition results in disruption of the mitotic checkpoint, and subsequent higher levels of aneuploid cells.
To date, Aurora B expression in osee was analyzed only in one previous series of40 cases (12) ; as in our cases, high level of staining was not found in any of the normal peritumoural tissue examined. Such results suggest a trend towards Aurora B overexpression in cancer. On the other side, we found no significant correlation between protein expression and tumour grade of differentiation.
In keeping with the few immunohistochemical studies on Aurora B expression in tumours (4), in our series Aurora B showed nuclear as well as cytoplasmic location, thus suggesting a possible intracellular translocation of this kinase which parallels the behaviour of survivin isoforms (25) . Survivin is a tumour-related protein, and a further member of the chromosome passenger complex (CPC) along with INCENP, and Borealin. Moreover, survivin belongs to the class of Aurora B substrates together with Histone H3, INCENP, CENP-A, desmin, Rec-8, vimentin (26) . Aurora B kinase is able to phosphorylate such proteins, and its activity is enhanced by survivin binding (27) . The mechanism involved in the survivin regulation of Aurora B kinase activity and the exact interaction between the three main chromosomal passenger proteins is speculative at the present time. The discrepancy regarding survivin cytoplasmic versus nuclear location lies in the fact that survivin exists in two immunochemically distinct subcellular pools, possibly as a result of alternatively spliced transcripts (28) . Evidence exists that some of the main substrates of Aurora B, i.e. survivin, Histone H3, may playa role in OSCC cancerogenesis, thus acting as novel therapeutic targets (16, 25, 29) .
Squamous cell carcinomas represent the vast majority of malignant tumours of the oral cavity and oropharynx; these aggressive epithelial malignancies are associated with a high overall rate of recurrence and early and extensive lymph node metastasis (I). Currently, their prognosis is still assessed on the basis of staging features (tumour size, lymph node involvement), since no molecular marker has been found carrying a reliable predictive potential. In our series, survival curves showed shorter time to progression in high-level Aurora B cases, and multivariate analysis showed that its expression can be considered an independent prognostic factor, able to modify cancer time to progression. As far as we know.this is the first study addressing the predictive role ofAurora B in OSCC, and our data may strongly recommend its use in order to stratify oral cancer patients into different risk groups on the basis of their Aurora B level of expression.
A number of small-molecule inhibitors targeting Aurora kinases have been developed first using gene silencing approaches such as siRNA and antisense oligonucleotides; most of them have been tested in preclinical studies and ongoing early-phase clinical trials, and a most recent in vitro study demonstrated that Aurora kinase inhibitory VX-680 is able to stimulate apoptotic cell death in OSCC cells (30) . We believe that such data deserve further studies on larger case series and specific clinical trials to be corroborated.
In summary, our study represents the first attempt to translate the biological finding of Aurora B overexpression in OSCC into a clinical setting, by providing data on the strong predictive role of this protein in a large series of patients. We suggest that immunohistochemical evaluation of Aurora B expression might be helpful in categorising patients into risk groups, and finally improve management strategies.
